CE study BEL vs csDMARDs in TriNetX Mortality ~3-4% for MTX/AZA/MMF vs ~1.5% for BEL, ~50% reduction in adjusted analysis Pretty surprising given mediocre results from BLISS RCTs, but strong research group & lotsa fancy stats Do you believe it? #ACR25 @RheumNow Abstr#0804 https://t.co/Yex98EYDjP

• https://x.com/EBRheum/status/1982518842867015986/photo/1
• https://x.com/EBRheum/status/1982518842867015986/photo/1

#ACR25 Abstr#802 In #SLE pts with CLASI-A ≥8, pooled post-hoc analysis of Phase 2 RCT showed enpatoran, oral small molecule toll-like receptor 7/8-i impoved cutaneous response vs PBO as early as WK4. First-in-class promising therapy & warrant investigation in Phase 3 @RheumNow https://t.co/rn6NXdiGjD

• https://x.com/Yuz6Yusof/status/1982517785134854228/photo/1
• https://x.com/Yuz6Yusof/status/1982517785134854228/photo/1

Urinary proteomics reveals promising biomarkers for ankylosing spondylitis. PIK3IP1 & SDC1 levels were significantly elevated in AS patients, showing strong diagnostic performance (AUCs: 0.852 & 0.875). Combined with AMY1A, the multiplex panel reached an AUC of 0.973. Abstract https://t.co/YUulKFqj8V

• https://x.com/synovialjoints/status/1982515068551024689/photo/1

Effect of BioDMARDs on Diabetes risk in 6400+ Psoriasis pts IL-23i and IL-17Ai associated w/ -lower risks of diabetes -Diabetic nephropathy -Stage 3–5 CKD and reduced risk compared to TNFi treated and bionaive pts Adjustment on several variables, but not disease severity https://t.co/TDIHXJOC2T

• https://x.com/AurelieRheumo/status/1982514480211693706/photo/1
• https://x.com/AurelieRheumo/status/1982514480211693706/photo/1

The benefits of exercise has been proven for most rheumatic diseases, and there are lots of good reasons why #ACR25 Brian Andonian @RheumNow https://t.co/IEErXL6ynL

• https://x.com/drdavidliew/status/1982514009577570359/photo/1

What is my risk of developing proteinuria? Hopkins Lupus Cohort developed a risk score predicting 10-year risk of new-onset proteinuria after SLE dx (n=1,418) @RheumNow #ACR25 https://t.co/Z0zPrG2NJ3

• https://x.com/AkhilSoodMD/status/1982512551347859921/photo/1

#ACR25 Abstr#801 Post-hoc analysis of Phase 2 RCT showed longer duration on Ianalumab (IAN) is beneficial. More #SLE pts achieved LLDAS or DORIS remission and GC taper in IAN in blinded 28-wk phase + open label IAN for the next 24-week group vs PBO-Open Label IAN @RheumNow https://t.co/I1Ugfj3BBl

• https://x.com/Yuz6Yusof/status/1982512157893050797/photo/1

A retrospective study from Spain assessed the relationship bet HPV infxn & biologic tx in SLE pts 🔅 Prevalence of HPV 9.9% 🔅 No significant assocs bet HPV infxn, biologic tx, SLE-related dse variables & HPV RF progression Still, emphasize HPV screening #ACR25 @RheumNow Abs0659 https://t.co/1YusM1nYPr

• https://x.com/RHEUMarampa/status/1982511293178491235/photo/1

#0777 Big news for VEXAS! 🎯 The first validated disease activity index (VEXAS-DAI) has been developed via international Delphi consensus. A 12-domain, 40-point tool to standardise assessment & power trials in this complex syndrome. Validation underway! @RheumNow #ACR25 https://t.co/DSeHb7eNeV

• https://x.com/DrMiniDey/status/1982510034925015534/photo/1

Redefining When to Biopsy the Kidney in Patients with SLE # Petri et al. ACR 2025 - Lupus nephritis may be seen in lower proteinuria too (69%) Happy to share similar results from our study-Padiyar S, As C, Gowri M, Mathew J. Lupus. 2024;33(13):1511-1517. @RheumNow

New biomarkers 14-3-3η multiplex autoantibody assay improves axSpA diagnosis, especially in HLA-B27– patients. Combined with CRP & HLA-B27, detection rose to 99% (training) & 91.4% (evaluation). In HLA-B27– cases, 14-3-3η lifted detection to 70.6% & 55%. Abstract 0531 @RheumNow

FDA Approves Obinutuzumab for Active Lupus Nephritis The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis. https://t.co/Wr3tG5izCi https://t.co/P8A5PUCIX0

• FDA Approves Obinutuzumab for Active Lupus Nephritis | RheumNow

#Cancers esp #hematologic & #lung are ⬆️in Pts w #inflammatory #rheum #diseases Odds ratios of hem malignancies are wide & risk stratification is imp Are we doing a good job? 🤔skin cancer screening ??- not as per general standards Abst#0172 #ACR25 @RheumNow @ACRheum https://t.co/Uve9knXD3o

• https://x.com/Janetbirdope/status/1982506974005871012/photo/1
• https://x.com/Janetbirdope/status/1982506974005871012/photo/1

Do you believe that patients w #rheumatic #diseases flare if #extreme #weather? Even 90 days after extreme weather events flares occur - loss of power, heat’ med storage = ++stressful events Is it early flare from weather & then ++stress @RheumNow @ACRrheum #ACR25 abst#0164 https://t.co/pGPwOKrKU7

• https://x.com/Janetbirdope/status/1982506545415180367/photo/1

Why do pts with #Still’s #AOSD Get hospitalized? #Sepsis 1827 unweighted & 9135 Weighted #US #hospitalizations Worse in men Black Medicaid But is it truly #infection or Still’s flare or both? Abst#0163 ACR25 @RheumNow @rheumacr #ACRBest as largest N ever! https://t.co/fLMNyQQNNj

• https://x.com/Janetbirdope/status/1982506217764450755/photo/1